Skip to main content
Article
Clinical Application of WHF-MOGE(S) Classification for Hypertrophic Cardiomyopathy
Glob Heart
  • Anushree Agarwal, M.D., Aurora St. Luke's Medical Center; Aurora Sinai Medical Center
  • Rayan Yousefzai, Aurora Health Care
  • M. Fuad Jan, Aurora Cardiovascular Services, Aurora Health Care
  • Chris Cho, Aurora Health Care
  • Kambiz Shetabi, Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care
  • Michelle Bush, Aurora Health Care
  • Bijoy K Khandheria, M.D., Aurora St. Luke's Medical Center; Aurora Sinai Medical Center
  • Timothy E Paterick, M.D., J.D., Aurora St. Luke's Medical Center; Aurora Sinai Medical Center
  • Shannon C Treiber, Aurora Health Care
  • Jasbir Sra, Aurora Sinai/Aurora St. Luke’s Medical Centers, Aurora Health Care
  • Paul H Werner, Aurora Health Care
  • Suhail Allaqaband, Aurora Sinai/Aurora St. Luke’s Medical Centers, Aurora Health Care
  • Tanvir Bajwa, Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care
  • A. Jamil Tajik, Aurora Cardiovascular Services, Aurora Health Care
Aurora Affiliations

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers

Publication Date
9-1-2015
Abstract

BACKGROUND: Recently, a new MOGE(S) (Morphofunctional, Organ involvement, Genetics, Etiology of details of the genetic disease or underlying cause, and functional Status) genotype to phenotype nosology system for classification of cardiomyopathies was proposed, but its clinical use has not been described.

OBJECTIVES: This study presents the comprehensive geno-phenotypic evaluation of hypertrophic cardiomyopathy (HCM) patients by employing the newly proposed World Heart Federation classification of cardiomyopathies - the MOGE(S) classification.

METHODS: From January 2011 to March 2014, 254 patients were evaluated (190 probands and 64 family members). Of those, 181 were HCM phenotype-positive probands, and 54.7% were male patients. Mean maximal left ventricular thickness was 2.2 ± 0.6 cm, with >2.5 cm thickness seen in 21.5% of patients. Obstructive HCM was present in 66.3% of patients, with an average peak gradient of 57.1 ± 47.2. Detailed clinical, imaging, and follow-up data were analyzed. Gene testing was performed in 129 patients (67.9%), and they were categorized into gene-positive (MHOHGADEG+) and gene-negative (MHOHGADEG-) groups based on the MOGE(S) classification.

RESULTS: MHOHGADEG+ patients were younger at time of diagnosis, more likely to be female, more likely to have ventricular tachycardia and a family history of HCM or sudden death, had lower peak gradients, and were more likely to have sudden death risk factors.

CONCLUSIONS: In addition to employing genotype-to-phenotype nosology to describe HCM, we propose a modification to the current MOGE(S) classification for HCM based on the presence or absence of obstruction and location of hypertrophy within the morphology.

Document Type
Article
PubMed ID
26271555
DOI
10.1016/j.gheart.2015.01.001
Citation Information
Agarwal A, Yousefzai R, Jan MF, et al. Clinical Application of WHF-MOGE(S) Classification for Hypertrophic Cardiomyopathy. Glob Heart. 2015 Sep;10(3):209-19.